SBP solbec pharmaceuticals limited

Solbec: Orphan Drug Status Clarification

  1. 404 Posts.
    This is an extract from Solbec's own website.

    "Developing a treatment for mesothelioma also opens up the Orphan Drug Program for the company. This is a program that results in a much more expeditious route to market with a reduced program of clinical testing and a fast track through the regulatory process. E.g. the Novartis product Gleevac took 9 weeks to pass through the US FDA where the average approval time is 29 months."

    Remember, this is only 1 (certainly the main one) of the products under development by Solbec.
    Visit their website to get the FULL picture; then understand that Orphan Drug Status is not the only matter that can move the price upwards.
watchlist Created with Sketch. Add SBP (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.